SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Magnesium Sulfate Injection (20ml: 10g, 10ml: 5g and 2ml: 1g) and Vortioxetine Hydrobromide Tablets (10mg) from the National Medical Products Administration of China, being under type 3 chemical drug and type 4 chemical drug respectively, and regarded as passing the consistency evaluation. As an anticonvulsant drug, Magnesium Sulfate Injection is a mainly used in pregnancy-induced hyper-tension for the treatment of pre-eclampsia and eclampsia by reducing blood pressure. Vortioxetine Hydrobromide Tablets is mainly used for the treatment of depression in adults.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.3 HKD | +0.23% |
|
-0.69% | -12.96% |
12:43pm | SSY Group Obtains Registration Go-Ahead for 2 Drugs from Chinese Regulator | MT |
07-16 | Chinese Regulator OKs SSY Group's Betahistine Mesilate Tablets for Drug Production, Registration | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.96% | 1.63B | |
+57.61% | 848B | |
+31.64% | 627B | |
-0.47% | 363B | |
+15.37% | 318B | |
+12.40% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.26% | 179B | |
+3.20% | 167B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- Ssy Group Limited Provides Update on Product Development